TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06430788: A Study of Emapalumab for Pediatric Aplastic Anemia

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 35 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,095,600

Rescue Site Savings

+$730,400

Unlock Full NCT06430788 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06430788 Rescue Dossier →